

Quarter End Statement of Investments

3rd Quarter as of September 30, 2026

Industry Allocation	% of Net Asset Value
Pharmaceuticals and Biotechnology	45.32%
Medical Equipment and Services	33.88%
Health Care Providers	21.00%
Cash & Cash Equivalents	0.11%
Total	100.31%
Other Assets and Liabilities	(0.31%)
Total Net Asset Value	100.00%

Top 25 Holdings	% of Net Asset Value
Natera, Inc.	3.36%
Regeneron Pharmaceuticals, Inc.	2.68%
Guardant Health, Inc.	2.62%
Pfizer, Inc.	2.61%
Universal Health Services, Inc. (Class B)	2.58%
Solventum Corporation	2.52%
Halozyme Therapeutics, Inc.	2.32%
Zimmer Biomet Holdings, Inc.	2.27%
Boston Scientific Corporation	2.25%
Tenet Healthcare Corporation	2.25%
Corcept Therapeutics, Inc.	2.18%
The Cigna Group	2.17%
Centene Corporation	2.13%
Globus Medical, Inc. (Class A)	2.09%
Encompass Health Corporation	1.98%
Medline, Inc. (Class A)	1.94%
ResMed, Inc.	1.87%
QIAGEN N.V.	1.84%
Medtronic Plc	1.82%
Doximity, Inc. (Class A)	1.81%
Incyte Corporation	1.76%
DaVita, Inc.	1.73%
Elevance Health, Inc.	1.66%
Axsome Therapeutics, Inc.	1.66%
United Therapeutics Corporation	1.65%
Total Net Asset Value	\$8,388,352

Commissions, management fees and expenses all may be associated with ETF investments. Please carefully read the simplified prospectus of the ETF before investing. ETFs are not guaranteed, their values change frequently and past performance may not be repeated. Data is as of September 30, 2026 (unaudited).